FTDI
REGN icon

First Trust Direct Indexing’s Regeneron Pharmaceuticals REGN Stock Holding History

First Trust Direct Indexing’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,842
Closed -$4.04M – 708
2024
Q3 		$4.04M Buy
3,842
+124
+3% +$138K 0.22% 85
2024
Q2 		$3.91M Buy
3,718
+337
+10% +$327K 0.24% 80
2024
Q1 		$3.25M Buy
3,381
+97
+3% +$92.2K 0.24% 81
2023
Q4 		$2.88M Buy
3,284
+61
+2% +$50.2K 0.26% 78
2023
Q3 		$2.65M Buy
3,223
+43
+1% +$33.8K 0.3% 56
2023
Q2 		$2.29M Sell
3,180
-185
-5% -$143K 0.25% 80
2023
Q1 		$2.77M Sell
3,365
-7
-0.2% -$5.28K 0.33% 51
2022
Q4 		$2.43M Buy
3,372
+55
+2% +$40.6K 0.32% 57
2022
Q3 		$2.29M Buy
3,317
+23
+0.7% +$14.5K 0.33% 51
2022
Q2 		$1.95M Sell
3,294
-149
-4% -$96.9K 0.27% 76
2022
Q1 		$2.4M Sell
3,443
-135
-4% -$85.4K 0.29% 63
2021
Q4 		$2.26M Sell
3,578
-84
-2% -$51.6K 0.29% 65
2021
Q3 		$2.22M Buy
3,662
+237
+7% +$147K 0.32% 58
2021
Q2 		$1.91M Buy
3,425
+2,474
+260% +$1.25M 0.29% 74
2021
Q1 		$450K Buy
951
+93
+11% +$45.3K 0.12% 237
2020
Q4 		$415K Buy
+858
New +$463K 0.11% 229

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

First Trust Direct Indexing's REGN Position: Q4 2024 in Review

First Trust Direct Indexing sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 3,842 shares — an estimated $4.04M sold.

First Trust Direct Indexing first reported a position in REGN in Q4 2020 and held it in 16 quarters. The position peaked at $4.04M in Q3 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • First Trust Direct Indexing reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • First Trust Direct Indexing sold 3,842 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $4.04M.
  • First Trust Direct Indexing first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 16 quarters.
  • First Trust Direct Indexing's Regeneron Pharmaceuticals position peaked at $4.04M in Q3 2024.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on First Trust Direct Indexing's 13F filing for Q4 2024.